Healthcare and Life Sciences

The DarrowEverett Health Care & Life Sciences Practice advises clients across the heavily regulated and consistently evolving health care and life sciences industry. Service providers including hospitals; facilities; manufacturers; suppliers; lenders; investors; academia; and healthcare technology, biotechnology, food and dietary supplement, insurance, medical device, and pharmaceutical companies turn to us for assistance with the myriad of legal and regulatory issues and challenges that they face day to day in their businesses.

The DE team has extensive experience in healthcare mergers, acquisitions, joint ventures; strategic positioning, restructuring, capital access, private equity investments, divestitures, and bankruptcies. We aid with licensing, tax issues, government investigations, employment matters, governance, regulatory compliance, and Medicare/Medicaid reimbursement disputes and have litigated complex disputes involving commercial transactions and allegations of fraud, anti-kickback, and false claims act violations.

Our clients that manufacture or market products regulated by the US Food and Drug Administration (FDA) must also deal with the constantly changing procedural, regulatory, and legislative matters surrounding compliance, enforcement and product development, approvals, launch, sales, and marketing, reporting obligations, disclosures, and recalls.

The DE Health Care Practice Group regularly advises clients on:

  • Mergers, Acquisitions, & Sales
  • Financing, Restructuring, & Leasing
  • Medicare & Medicaid Reimbursement Disputes
  • Intellectual Property Issues
  • Licensure & Credentialing
  • Heath Insurance Portability & Accountability Act
  • Anti-kickback Laws
  • Corporate Integrity Agreements
  • Corporate, Regulatory, & Security Compliance
  • Employment, Contracting, & Negotiation
  • Stark Law
  • False Claims Act
  • Qui Tam Actions
  • FDA Registration
  • Health Information Technology
  • Litigation, Arbitration, & Administrative Hearings
  • Government Enforcement Actions
  • Federal & State Regulatory Compliance
  • Products Liability
  • Strategic Positioning
  • Senior & Elder Care Services
  • Clinical Investigations
  • Dispute Resolution
  • Labeling, Advertising, & Promotion
  • Product Recalls

Practice Leader

Kevin P. Gildea - Partner


Kevin P. Gildea is a Partner and the Practice Leader for DarrowEverett’s Healthcare and Life Sciences, a Practice Leader in its Regulatory & Compliance Practice Group, a Practice Leader in the Data Privacy & Cybersecurity Group, and the co-head of the Corporate Department. He has a practice concentrated in the areas of corporate, banking, healthcare and life sciences, renewable energy, non-profit, and financial services regulation, compliance, litigation and enforcement defense, and transaction and merger-acquisition related structuring,...

Read more

Contact our Healthcare and Life Sciences Group.

Please contact us to let us know how DarrowEverett can serve you.

    DE Insights

    Our team wants you to stay informed about legal and regulatory developments that impact your business.

    Diversity Driven Derivative Suits: Culture Wars Come to the Boardroom

    Traditionally deployed to protect a corporation from its board’s imprudent investment or financial decision-making, in recent years shareholders have taken to bringing derivative actions on a corporation’s behalf for its board’s alleged failure to pay more than lip service to the diversity, equity and inclusion (“DEI”) commitments the company publicly proclaims. Spurred in 2020 in…
    Read more

    Court Rulings Demonstrate That Privilege Is Not Always a Right

    Earlier this year, following oral argument and 16 amicus submissions, the Supreme Court dismissed as improvidently granted (“DIG”)[1] a writ of certiorari on the issue of whether communications involving both legal and non-legal advice are protected by the attorney-client privilege.[2] This red-hot issue was granted review following the decision styled In Re Grand Jury, in…
    Read more

    Danger, Does Not Compute: SEC Takes Aim at Predictive Data Analytics Per Proposed Rules

    On July 26, 2023, the Securities and Exchange Commission (“SEC”), in a 3-2 vote, issued a release (the “Release”) containing proposed rules to address conflicts of interest associated with broker dealers’ and investment advisers’ use of predictive data analytics (“PDA”) technologies, and PDA-like technologies, when interacting with investors.[1] The SEC’s proposed rules amend Rules 151-2,…
    Read more